Analysis of baseline visits that occurred during trimesters 1 and 2 (n=53)
| Marker | APO (n=14) | PE at any time (n=11) | Preterm delivery (n=10) | |||
| T-test (p value) | DOR (95% CI) | T-test (p value) | DOR (95% CI) | T-test (p value) | DOR (95% CI) | |
| ECR1 | 0.05 | 12.33 (2.41 to 63.10) | 0.37 | 4.11 (0.88 to 19.27) | 0.06 | 12.19 (2.30 to 64.72) |
| EC4d | 0.45 | 0.93 (0.25 to 3.46) | 0.18 | 3.89 (0.75 to 20.25) | 0.50 | 0.82 (0.19 to 3.48) |
| C3 | 0.87 | 0.38 (0.04 to 3.43) | 0.33 | 0.56 (0.06 to 5.11) | 0.85 | 0.64 (0.07 to 5.98) |
| C4 | 0.24 | 1.48 (0.37 to 5.97) | 0.74 | 0.70 (0.13 to 3.84) | 0.78 | 1.65 (0.35 to 7.82) |
| Anti-dsDNA | 0.73 | 1.05 (0.30 to 3.68) | 0.77 | 1.01 (0.27 to 3.83) | 0.70 | 0.96 (0.23 to 4.06) |
| LAC | NA | 0.90 (0.21 to 3.94) | NA | 3.54 (0.86 to 14.58) | NA | 1.70 (0.36 to 8.05) |
| Anti-PS/PT IgG | 0.18 | 1.53 (0.38 to 6.16) | 0.06 | 3.54 (0.86 to 14.58) | 0.11 | 3.11 (0.69 to 14.01) |
| aCL IgG | 0.53 | 1.53 (0.38 to 6.16) | 0.15 | 3.54 (0.86 to 14.58) | 0.23 | 3.11 (0.69 to 14.01) |
| Anti-β2-GP1 IgG | 0.47 | 1.04 (0.27 to 4.03) | 0.11 | 3.84 (0.96 to 15.31) | 0.38 | 2.13 (0.49 to 9.30) |
DOR and p value determined by t-test for ECR1, EC4d, complement proteins C3 and C4, anti-dsDNA, LAC and antiphospholipid antibodies (anti-PS/PT, aCL and anti-β2-GP1) are reported. LAC results are provided as positive or negative. As the t-test could not be performed for LAC, p values are not reported for LAC (NA) in the table. PE at any time includes the pregnancies that presented with PE before (n=7) and after (n=4) the 36th week of gestation.
aCL, anticardiolipin; anti-dsDNA, anti-double-stranded DNA; anti-PS/PT, antiphosphatidylserine prothrombin complex; anti-β2-GP1, anti-β2 glycoprotein 1; APO, adverse pregnancy outcomes; DOR, diagnostic OR; EC4d, erythrocyte-bound C4d; ECR1, erythrocyte complement receptor 1; LAC, lupus anticoagulant; NA, not available; PE, pre-eclampsia.